A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV) Antiviral Market

All-oral Regimens Revolutionize the Market

Regular Price: USD 3,950

Special Price USD 3,555

10% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 3,555

PAY BY INVOICE

Be the first to review this product

This research service focuses on antiviral therapeutics for the treatment of the hepatitis C virus (HCV). A global product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HCV. Segmentation by drug class is provided, along with supporting information such as clinical trial timelines and results, key market developments, historical and projected launch timelines, and epidemiology. The information contained in this research was derived from published sources, including disease organizations; public health organizations; company publications including annual reports, SEC filings, and press releases; government public sources; and articles in scientific journals.

Table of Contents

Executive SummaryKey Market Developments Since Q1 2013Key FindingsEvolution of Standard of Care for HCVKey Companies to WatchMethodology and ScopeMethodology and ScopeIntroductionHCV OverviewGlobal Prevalence of Chronic HCV Infection by RegionGlobal HCV Genotype Distribution and Relative Prevalence HCV Antiviral Market—SegmentationHCV Antiviral Market—Segmentation (continued)Competitive AnalysisCompetitive Landscape—Marketed Products and Products in DevelopmentCompetitive Landscape—All-oral Regimens Late Stage Clinical DataCompetitive Landscape—Projected Launch Timeline for Oral RegimensCompetitive Landscape—Major Phase 3 Trials for All-oral RegimensCompetitive Landscape—Major Phase 3 Trials for All-oral Regimens (continued)Competitive Landscape—Late Stage Assets by Company and ClassMarketed Products Synopsis—Standard of CareMarketed Products Synopsis—Add-on to Standard of CareMarketed Products Synopsis—Global Introduction by RegionMarketed Products Synopsis—Global Introduction by Region (continued)Pipeline Synopsis—All-oral Regimens in Clinical DevelopmentPipeline Synopsis—All-oral Regimens in Clinical Development (continued)Pipeline Synopsis—All-oral Regimens in Clinical Development (continued)Pipeline Synopsis—Late Stage Clinical Development LandscapePipeline Synopsis—Late Stage Clinical Development Landscape (continued)Pipeline Synopsis—Late Stage Clinical Development Landscape (continued)Pipeline Synopsis—Late Stage Clinical Development Landscape (continued)Pipeline Synopsis—Late Stage Clinical Development Landscape (continued)Pipeline Synopsis—Late Stage Clinical Development Landscape (continued) Pipeline Synopsis—Early Clinical Development LandscapePipeline Synopsis—Early Clinical Development Landscape (continued)Pipeline Synopsis—Early Clinical Development Landscape (continued)Conclusions and RecommendationsConclusions and Recommendations Conclusions and Recommendations (continued)Legal DisclaimerAppendixDecision Support DatabaseDecision Support Database (continued)Decision Support Database (continued)Decision Support Database (continued) The Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.